<DOC>
	<DOCNO>NCT01682070</DOCNO>
	<brief_summary>The aim study determine optimal effective dose SUBLIVAC FIX Phleum pratense base reduction upper airways reactivity 5 month treatment different dosage SUBLIVAC FIX Phleum pratense compare placebo . Furthermore , safety tolerability assess number related Adverse Events different dosage SUBLIVAC FIX Phleum pratense compare placebo .</brief_summary>
	<brief_title>SUBLIVAC FIX Phleum Pratense DT/DRF</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>Signed informed consent Age ≥ 18 ≤ 60 year Allergic rhinitis/rhinoconjunctivitis related grass pollen without concomitant mild moderate persistent asthma FEV1 &gt; 70 % patient history asthma , FEV &gt; 70 % PEF &gt; 80 % patient without history asthma A positive SPT ( mean wheal diameter ≥ 3mm compare negative control negative control negative ) grass pollen assess within 1 year randomization . Positive serum specific antigrass IgEtest ( &gt; 0.7 U/mL ) A positive TNPT grass pollen screening ( Lebel score ≥ 6 ) ≤10,000 AU/mL Patients ( expect ) clinically relevant symptom course trial due concomitant sensitization i.e . positive SPT ( mean wheal diameter ≥ 3mm ) allergen grass pollen Patients sensitize pet include regularly expose pet symptomatic upon exposure pet Completed immunotherapy ( SCIT SLIT ) grass pollen allergen within past 5 year Completed unsuccessful specific immunotherapy past Vaccination within one week start therapy initiation phase AntiIgE therapy within 6 month prior inclusion study Severe immune disorder ( include autoimmune disease ) and/or disease require immunosuppressive drug Active malignancy malignant disease previous 5 year Severe uncontrolled disease could increase risk patient participate study , include limited : cardiovascular insufficiency , severe unstable lung disease , endocrine disease , clinically significant renal hepatic disease , haematological disorder Active inflammation infection target organ ( nose , eye low airway ) start study Moderate severe nasal obstructive disease preclude TNPT ( septal deviation , nasal polyp , recent nasal surgery , etc . ) Diseases contraindication use Adrenaline ( e.g . hyperthyroidism , glaucoma ) Use systemic steroid within 4 week start study study Treatment systemic local βblockers Participation clinical study new investigational drug within last 3 month biological within last 6 month prior study Pregnancy , lactation inadequate contraceptive measure woman childbearing age ( adequate contraceptive measure use contraceptive device pill ) Alcohol , drug medication abuse within past year Any clinically significant abnormal laboratory parameter screen Lack cooperation compliance Severe psychiatric , psychological , neurological disorder Patients employee institution 1st grade relative partner investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Sublingual immunotherapy</keyword>
	<keyword>Dose range find</keyword>
	<keyword>Dose tolerability</keyword>
	<keyword>grass pollen</keyword>
	<keyword>Allergic rhinitis/rhinoconjunctivitis</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>